Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02646917 · ClinicalTrials.gov registry record · NA

SkinPen Efficacy on Acne Scars on the Face and/or Back

A NA study of Atrophic Acne Scar, sponsored by Bellus Medical.

Completed
Registry status
NA
Development phase
41
Enrollment target
1
Study location

NCT02646917 is a NA study of Atrophic Acne Scar that has completed, run by Bellus Medical. The registered enrollment target is 41 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02646917, a NA study of Atrophic Acne Scar, has completed, sponsored by Bellus Medical.

COMPLETED
Registry status
NA
Development phase
41 participants
Enrollment target
1
Study location

Study Summary

This single-center, clinical trial will take place over a 90 day course followed by 1-month and 6-month post treatment visits to assess the efficacy and tolerability of the SkinPen device when used on both men and women on the face and/or back.

Conditions Studied

Interventions

  • PROCEDURE Aesthetic Microneedling Treatment

Study Locations (1)

Texas

  • Stephens & Associates - Richardson

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2015-12
Est. Completion 2017-07-25
Phase NA

Sponsor

Bellus Medical

2 total trials

What the Registry Record Tells You About NCT02646917

The ClinicalTrials.gov registry entry for NCT02646917 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bellus Medical, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atrophic Acne Scar appearing as the primary indexed condition, and to 1 intervention - of which Aesthetic Microneedling Treatment is the first listed.

NCT02646917 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02646917 about?

NCT02646917 is a clinical study titled "SkinPen Efficacy on Acne Scars on the Face and/or Back". This single-center, clinical trial will take place over a 90 day course followed by 1-month and 6-month post treatment visits to assess the efficacy and tolerability of the SkinPen device when used on both men and women on the face and/or back.

What is the current status of trial NCT02646917?

This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2015-12. Estimated completion is 2017-07-25.

What conditions does trial NCT02646917 study?

This clinical trial studies the following conditions: Atrophic Acne Scar.

What interventions are being tested in trial NCT02646917?

The interventions under investigation include: Aesthetic Microneedling Treatment (PROCEDURE).

Who is sponsoring clinical trial NCT02646917?

This trial is sponsored by Bellus Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02646917 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.